Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.

Background: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome.

Objective: To identify patients at risk of unfavourable outcomes who may benefit from the new drugs.

Methods: Retrospective cohort study of treatment outcomes involving four to five effective drugs for 15-24 months in programmes in Uzbekistan, Georgia, Armenia, Swaziland and Kenya between 2001 and 2011.